Patent · US Expired

(1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane

US7354937B2 · kind B2 · utility

1Cited by

0References

4Claims

0Family size

Assignee

Abbott Laboratories · US

Inventors

Michael Buckley · Ingleside, US
Jianguo Ji · Shanghai, CN
Geoff G. Z. Zhang · Libertyville, US
Rodger F. Henry · Park City, US
Weili W. Wang · Buffalo Grove, US
Gregory S. Wayne · Vernon Hills, US
Wenke Li · Gurnee, US
Timothy B. Towne · Lindenhurst, US
Steven J. Wittenberger · Mundelein, US
Steven M. Hannick · Highland Park, US
Brian J. Kotecki · Oak Creek, US
Bryan S. Macri · Gurnee, US
Timothy A. Robbins · Gurnee, US

Key dates

Filing date	Jul 7, 2005
Grant date	Apr 8, 2008
Priority date	—
Expiry date	Jul 7, 2025

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P25/28
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention discloses (1S,5S)-3-(5,6-dichloro-3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane, salts thereof, and its use to treat pain and other disorders associated with the nicotinic acetylcholine receptor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.